The stock of Vaxcyte Inc (PCVX) has gone up by 1.58% for the week, with a 4.84% rise in the past month and a -11.56% drop in the past quarter. The volatility ratio for the week is 3.17%, and the volatility levels for the past 30 days are 3.47% for PCVX. The simple moving average for the last 20 days is 4.47% for PCVX’s stock, with a simple moving average of 12.49% for the last 200 days.
Is It Worth Investing in Vaxcyte Inc (NASDAQ: PCVX) Right Now?
The 36-month beta value for PCVX is at 0.95. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PCVX is 103.26M, and currently, shorts hold a 7.98% of that float. The average trading volume for PCVX on May 10, 2024 was 715.26K shares.
PCVX) stock’s latest price update
Vaxcyte Inc (NASDAQ: PCVX) has experienced a decline in its stock price by -1.83 compared to its previous closing price of 66.79. However, the company has seen a gain of 1.58% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-02 that SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT.
Analysts’ Opinion of PCVX
Many brokerage firms have already submitted their reports for PCVX stocks, with Mizuho repeating the rating for PCVX by listing it as a “Buy.” The predicted price for PCVX in the upcoming period, according to Mizuho is $69 based on the research report published on December 07, 2023 of the previous year 2023.
Needham gave a rating of “Buy” to PCVX, setting the target price at $58 in the report published on January 03rd of the previous year.
PCVX Trading at -1.06% from the 50-Day Moving Average
After a stumble in the market that brought PCVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.08% of loss for the given period.
Volatility was left at 3.47%, however, over the last 30 days, the volatility rate increased by 3.17%, as shares surge +1.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.70% lower at present.
During the last 5 trading sessions, PCVX rose by +1.58%, which changed the moving average for the period of 200-days by +38.51% in comparison to the 20-day moving average, which settled at $62.80. In addition, Vaxcyte Inc saw 4.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCVX starting from Wassil Jim, who sale 3,000 shares at the price of $61.65 back on May 01 ’24. After this action, Wassil Jim now owns 215,462 shares of Vaxcyte Inc, valued at $184,942 using the latest closing price.
PICKERING GRANT, the CHIEF EXECUTIVE OFFICER of Vaxcyte Inc, sale 2,616 shares at $61.70 during a trade that took place back on May 01 ’24, which means that PICKERING GRANT is holding 146,054 shares at $161,419 based on the most recent closing price.
Stock Fundamentals for PCVX
Current profitability levels for the company are sitting at:
- -30.2 for the present operating margin
- 0.46 for the gross margin
The net margin for Vaxcyte Inc stands at -30.24. The total capital return value is set at -0.22. Equity return is now at value -29.83, with -28.19 for asset returns.
Based on Vaxcyte Inc (PCVX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -14.89. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -40.66.
Currently, EBITDA for the company is -382.87 million with net debt to EBITDA at 1.42. When we switch over and look at the enterprise to sales, we see a ratio of 453.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.42.
Conclusion
In conclusion, Vaxcyte Inc (PCVX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
